Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boehringer/WellPoint Outcomes Research To Inform Pradaxa Treatment

This article was originally published in The Pink Sheet Daily

Executive Summary

The study in non-valvular atrial fibrillation patients is the first project to launch under a five-year research agreement between Boehringer Ingelheim and WellPoint.

You may also be interested in...

Boehringer And Anthem Put Stiolto Duo To Real World Test In COPD

US noninferiority study mainly of Anthem beneficiaries aims to show if COPD patients are being overtreated with LABA/LAMA/ICS triple combos when a LABA/LAMA duo would do.

BI’s Pradaxa Gets Mixed Reviews In Postmarketing Studies

Two observational studies of Medicare patients reach different conclusions on Pradaxa bleeding rates, but FDA says risk/benefit profile of drug has not changed.

Boehringer Avoids Pradaxa Trial, Board Chair Deposition With $650 Mil. Settlement

Settlement expected to resolve approximately 4,000 Pradaxa personal injury claims.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts